News | Breast Imaging | July 29, 2021

Volpara Collaborates with Invitae Corporation for Genetic Testing Services

Collaboration expands access to genetic testing and risk assessment capabilities available through Volpara's breast health platform

Volpara Health, a global health technology software leader providing an integrated breast care platform for the delivery of personalized breast care, has signed an agreement with Invitae Corporation, a leader in medical genetics, to bring Invitae's genetic testing services to Volpara's customers in the United States. 

July 29, 2021 — Volpara Health, a global health technology software leader providing an integrated breast care platform for the delivery of personalized breast care, has signed an agreement with Invitae Corporation, a leader in medical genetics, to bring Invitae's genetic testing services to Volpara's customers in the United States. 

Volpara's United States customers will gain access to Invitae's comprehensive genetic testing services within Volpara's software workflow. Volpara plans to create an integrated ordering process for Invitae genetic testing services within its suite of products to provide women with additional access to comprehensive genetic testing services through a variety of clinical settings. 

Customers can utilize Volpara's market-leading breast cancer risk assessment software to confidently make informed decisions for triaging patients to supplemental imaging and/or genetic testing based on their personalized risk. Risk assessment is also required by insurance companies in the United States to justify reimbursement for additional testing. Along with supplemental screening, such as ultrasound and MRI, genetic testing assists in earlier cancer detection and is critical in reducing treatment costs and increasing the chances of survival. 

"Volpara continues to be proud of its major role in improving access to genetic testing and risk assessment critical to drive adoption of personalized breast screening in the United States. Our relationship with Invitae adds a prominent lab to the genetic services available through our breast health platform and will allow us to offer increased value to customers by ensuring that the right patients get seamless access to the right genetic testing at the right time," said Ralph Highnam, M.D., Group CEO of Volpara.

"While the value of genetic information in cancer care is well established, the ability to combine genetics with breast density and other forms of risk assessment to guide patient care remains underutilized," said Robert Nussbaum, M.D., chief medical officer of Invitae. "In working with Volpara, we want to make it easier for clinicians and oncologists to access genetic testing services to ensure that their patients have comprehensive and personalized medical information to better inform their healthcare decisions.

For more information: www.volparahealth.com

Related Content

Plan to attend RSNA21 at McCormick Place Chicago, Nov. 28 – Dec. 2, 2021

Getty Images

News | RSNA | September 13, 2021
September 13, 2021 — The Radiological Society of North America (RSNA) today announced highlights of the Technical Exh
This certification, which covers Agfa HealthCare’s Class IIa Enterprise Imaging and XERO Viewer solutions, ensures that Agfa HealthCare can continue to deliver to customers innovative solutions that meet their real challenges and address their needs and requirements.
News | Enterprise Imaging | September 09, 2021
September 9, 2021 — Agfa HealthCare is proud to be one of the first companies to receive the new European Medical Dev
According to ARRS’ American Journal of Roentgenology (AJR), immediately reading screening mammograms during the coronavirus disease (COVID-19) pandemic promises a new and improved paradigm—reducing care disparities, while increasing the speed of diagnostic workup.

Flow Chart of Patient Selection

News | Breast Imaging | September 09, 2021
September 9, 202
Laws designed to help women with increased risk for missed breast cancer diagnoses may help catch the disease earlier, according to Penn State College of Medicine researchers.

Getty Images | AleksandarNakic

News | Breast Imaging | September 09, 2021
September 9, 2021 — Laws designed to help women with increased risk for...
Insignia Medical Systems, a leading UK-based enterprise imaging provider, announced it has been acquired by Intelerad Medical Systems, a global leader in medical image management solutions. The deal signals an important step in expanding next-generation imaging solutions and resources to help modernise hospital trusts across the UK. 

Getty Images

News | Radiology Business | September 08, 2021
September 8, 2021 — Insignia Medical Systems, a leadi
Videos | Enterprise Imaging | September 03, 2021
ITN Editor Dave Fornell collected numerous examples of how...
Canon's Vitrea PACS enterprise imaging system was one of several systems demonstrated at HIMSS 2021 that had easily modified hanging protocols. This included ease of use to customize what each radiologists prefers, including slice thickness. #HIMSS #HIMSS21

Canon's Vitrea PACS enterprise imaging system was one of several systems demonstrated at HIMSS 2021 that had easily modified hanging protocols. This included ease of use to customize what each radiologists prefers, including slice thickness. Photo by Dave Fornell

Feature | Enterprise Imaging | September 02, 2021
Taking advantage of new technology advances, several ...
The researchers say there is currently a lack of good quality evidence to support a policy of replacing human radiologists with artificial intelligence (AI) technology when screening for breast cancer.

Getty Images

News | Artificial Intelligence | September 02, 2021
September 2, 2021 — Humans still seem to be better than technology when it comes to the accuracy of spotting possible
Mount Sinai scientists created an AI-based, automated system that learns to read patient data from electronic health records. Here the system identified dementia cases (purple dots) from a database of nearly 2 million patients (blue dots). Courtesy of the Glicksberg lab, Mount Sinai, N.Y., N.Y.

Mount Sinai scientists created an AI-based, automated system that learns to read patient data from electronic health records. Here the system identified dementia cases (purple dots) from a database of nearly 2 million patients (blue dots). Courtesy of the Glicksberg lab, Mount Sinai, N.Y., N.Y.

News | Artificial Intelligence | September 02, 2021
September 2, 2021 — In an article published in the journ...